论文部分内容阅读
目的:探讨分析二甲双胍联合甘精胰岛素治疗初诊肥胖2型糖尿病的临床疗效。方法:将2015年4月~2016年6月我院78例初诊2型糖尿病伴肥胖患者随机分为对照组与试验组各39例。对照组单独应用甘精胰岛素治疗,试验组应用二甲双胍+甘精胰岛素治疗,比较两组临床疗效及低血糖发生情况。结果:治疗12周后,试验组血糖、血脂水平均显著优于对照组(p<0.05);试验组低血糖发生率为12.82%,明显低于对照组28.21%(P<0.05)。结论:二甲双胍联合甘精胰岛素是治疗初诊2型糖尿病伴肥胖的有效降糖方案,能够有效降低患者血糖及血脂水平,减少低血糖事件发生。
Objective: To investigate the clinical efficacy of metformin combined with insulin glargine in the treatment of newly diagnosed obese type 2 diabetes. Methods: From April 2015 to June 2016, 78 newly diagnosed type 2 diabetic patients with obesity in our hospital were randomly divided into control group and experimental group, with 39 cases in each group. The control group was treated with insulin glargine alone, and the experimental group was treated with metformin plus insulin glargine. The clinical efficacy and the incidence of hypoglycaemia were compared between the two groups. Results: After 12 weeks of treatment, the levels of blood glucose and blood lipid in the experimental group were significantly better than those in the control group (p <0.05). The incidence of hypoglycemia in the experimental group was 12.82%, which was significantly lower than that in the control group (28.21%, P <0.05). CONCLUSION: Metformin combined with insulin glargine is an effective hypoglycemic regimen for the treatment of newly diagnosed type 2 diabetes with obesity, which can effectively reduce blood glucose and blood lipid levels and reduce the incidence of hypoglycaemia.